Natco Pharma Proposes Rights Issue of Equity Shares Up to ₹13,000 Million
Natco Pharma proposes a Rights Issue of Equity Shares to raise up to ₹13,000 million. The issue price is ₹[●] per share. Eligible shareholders will receive [●] shares for every [●] held. The Draft Letter of Offer was submitted on September 9, 2026.
A rights issue can impact the company's capital structure and potentially dilute existing shareholders' holdings if not fully subscribed or if the funds are not deployed effectively. The amount being raised is significant, hence the medium impact.
The announcement is a proposal for a rights issue and a submission of a draft letter of offer. While it indicates a capital raising activity, the specifics of the issue (price, ratio, dates) are yet to be finalized, making the immediate sentiment neutral.
Natco Pharma Limited has announced its proposal to undertake a Rights Issue of Equity Shares, subject to necessary regulatory and statutory approvals. The company has submitted a Draft Letter of Offer in this regard.
The proposed Rights Issue aims to raise up to ₹13,000 million (approximately $1,560 million USD converted to INR at 83 INR/USD) by issuing fully paid-up equity shares of face value ₹2 each. The issue price is set at ₹[●] per rights equity share, including a premium of ₹[●]. The shares will be offered on a rights basis to eligible equity shareholders in the ratio of [●] rights equity shares for every [●] fully paid-up equity share held as of the record date, which is yet to be determined.
The company has outlined an issue program with placeholders for key dates, including the Issue Opening Date, Last Date for On Market Renunciation of Rights Entitlements, Issue Closing Date, Finalisation of Basis of Allotment, Date of Allotment, Date of Credit of Rights Equity Shares, and Date of Listing. The Draft Letter of Offer is dated September 9, 2026.
What to do with a filing like this
Natco Pharma Limited filed this with the NSE as a statutory disclosure, categorised under rights issue. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Natco Pharma Limited. Read the original for the full detail.